This article was originally published in The Gray Sheet
Executive SummaryReceives FDA go-ahead to modify the labeling for the Physio-Stim Lite bone growth stimulator by removing the stipulation that surgeons wait nine months from the start of a non-union fracture before prescribing the device. The change "will make it more likely that surgeons and third party insurance organizations will use these devices" on patients with non-union fractures, the Richardson, Texas-based firm maintains
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.